• NDC Code(s): 0527-5406-68, 0527-5406-70
  • Packager: Lannett Company, Inc.
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated February 14, 2024

If you are a consumer or patient please visit this version.


    Rx only


    Prednisolone Syrup (Prednisolone Oral Solution, USP) contains prednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisolone is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water; soluble in methanol and in dioxane; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.

    The chemical name for prednisolone is Pregna-1,4-diene-3,20-dione,11,17,21-trihydroxy-,(11β).

    This is an image of the structural formula of Prednisolone.

    Prednisolone Syrup (Prednisolone Oral Solution, USP) contains 15 mg of prednisolone in each 5 mL. Benzoic acid, 0.1% is added as a preservative. It also contains alcohol 5% v/v, cherry flavor, citric acid, edetate disodium, FD&C Blue #1, FD&C Red #40, glycerin, propylene glycol, purified water, sodium saccharin, and sucrose. Prednisolone Syrup (Prednisolone Oral Solution, USP) may contain sodium citrate for pH adjustment.


    Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs such as prednisolone are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

    Glucocorticoids such as prednisolone cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.


    Prednisolone Syrup (Prednisolone Oral Solution, USP) is indicated in the following conditions:

    1. Endocrine Disorders

    Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).

         Congenital adrenal hyperplasia

         Nonsuppurative thyroiditis

         Hypercalcemia associated with cancer

    2. Rheumatic Disorders

    As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

         Psoriatic arthritis

         Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

         Ankylosing spondylitis

         Acute and subacute bursitis

         Acute nonspecific tenosynovitis

         Acute gouty arthritis

         Post-traumatic osteoarthritis

         Synovitis of osteoarthritis


    3. Collagen Diseases

    During an exacerbation or as maintenance therapy in selected cases of:

         Systemic lupus erythematosus

         Acute rheumatic carditis

    4. Dermatologic Diseases


         Bullous dermatitis herpetiformis

         Severe erythema multiforme (Stevens-Johnson syndrome)

         Exfoliative dermatitis

         Mycosis fungoides

         Severe psoriasis

         Severe seborrheic dermatitis

    5. Allergic States

    Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

         Seasonal or perennial allergic rhinitis

         Bronchial asthma

         Contact dermatitis

         Atopic dermatitis

         Serum sickness

         Drug hypersensitivity reactions

    6. Ophthalmic Diseases

    Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

         Allergic corneal marginal ulcers

         Herpes zoster ophthalmicus

         Anterior segment inflammation

         Diffuse posterior uveitis and choroiditis

         Sympathetic ophthalmia

         Allergic conjunctivitis



         Optic neuritis

         Iritis and iridocyclitis

    7. Respiratory Diseases

    Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means


         Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy

         Aspiration pneumonitis

    8. Hematologic Disorders

    Idiopathic thrombocytopenic purpura in adults

    Secondary thrombocytopenia in adults

    Acquired (autoimmune) hemolytic anemia

    Erythroblastopenia (RBC anemia)

    Congenital (erythroid) hypoplastic anemia

    9. Neoplastic Diseases

    For palliative management of:

         Leukemias and lymphomas in adults

         Acute leukemia of childhood

    10. Edematous States

    To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

    11. Gastrointestinal Diseases

    To tide the patient over a critical period of the disease in:

         Ulcerative colitis

         Regional enteritis

    12. Miscellaneous

    Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

    In addition to the above indications Prednisolone Syrup (Prednisolone Oral Solution, USP) is indicated for systemic dermatomyositis (polymyositis).


    Systemic fungal infections.


    In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

    Immunosuppression and Increased Risk of Infection

    Corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP), suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:

    • Reduce resistance to new infections
    • Exacerbate existing infections
    • Increase the risk of disseminated infections
    • Increase the risk of reactivation or exacerbation of latent infections
    • Mask some signs of infection

    Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

    Monitor for the development of infection and consider Prednisolone Syrup (Prednisolone Oral Solution, USP) withdrawal or dosage reduction as needed.

    Do not administer Prednisolone Syrup (Prednisolone Oral Solution, USP) by an intraarticular, intrabursal, intratendinous, or intralesional route in the presence of acute local infection.


    If Prednisolone Syrup (Prednisolone Oral Solution, USP) is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged Prednisolone Syrup (Prednisolone Oral Solution, USP) therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.

    Varicella Zoster and Measles Viral Infections

    Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP). In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles:

    • If a Prednisolone Syrup (Prednisolone Oral Solution, USP)-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
    •  If a Prednisolone Syrup (Prednisolone Oral Solution, USP)-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

    Hepatitis B Virus Reactivation

    Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP). Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.

    Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with Prednisolone Syrup (Prednisolone Oral Solution, USP). For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

    Fungal Infections

    Corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP), may exacerbate systemic fungal infections; therefore, avoid Prednisolone Syrup (Prednisolone Oral Solution, USP) use in the presence of such infections unless Prednisolone Syrup (Prednisolone Oral Solution, USP) is needed to control drug reactions. For patients on chronic Prednisolone Syrup (Prednisolone Oral Solution, USP) therapy who develop systemic fungal infections, Prednisolone Syrup (Prednisolone Oral Solution, USP) withdrawal or dosage reduction is recommended.


    Corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP), may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating Prednisolone Syrup (Prednisolone Oral Solution, USP) in patients who have spent time in the tropics or patients with unexplained diarrhea.

    Strongyloides Infestation

    Corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP), should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

    Cerebral Malaria

    Avoid corticosteroids, including Prednisolone Syrup (Prednisolone Oral Solution, USP), in patients with cerebral malaria.

    Kaposi’s Sarcoma

    Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.

    Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

    Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

    While on corticosteroid therapy, patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.

    Use in Pregnancy: Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.



    Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

    There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

    Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

    The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

    Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

    Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

    Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

    Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

    Information for Patients:

    Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.


    Fluid and Electrolyte Disturbances
    Sodium retention
         Fluid retention
         Congestive heart failure in susceptible patients
         Potassium loss
         Hypokalemic alkalosis

         Muscle weakness
         Steroid myopathy
         Loss of muscle mass
         Vertebral compression fractures
         Aseptic necrosis of femoral and humeral heads
         Pathologic fracture of long bones

         Peptic ulcer with possible perforation and hemorrhage
         Abdominal distention
         Ulcerative esophagitis

         Impaired wound healing
         Thin fragile skin
         Petechiae and ecchymoses
         Facial erythema
         Increased sweating
         May suppress reactions to skin tests

         Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment

         Menstrual irregularities
         Development of Cushingoid state
         Suppression of growth in children
         Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness
         Decreased carbohydrate tolerance
         Manifestations of latent diabetes mellitus
         Increased requirements for insulin or oral hypoglycemic agents in diabetics

         Posterior subcapsular cataracts
         Increased intraocular pressure

    Negative nitrogen balance due to protein catabolism

    To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-800-FDA-1088 or


    Dosage of Prednisolone Syrup (Prednisolone Oral Solution, USP) should be individualized according to the severity of the disease and the response of the patient. For infants and children, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.

    Hormone therapy is an adjunct to and not a replacement for conventional therapy.

    Dosage should be decreased or discontinued gradually when the drug has been administered for more than a few days.

    The severity, prognosis, expected duration of the disease, and the reaction of the patient to medication are primary factors in determining dosage.

    If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued.

    Blood pressure, body weight, routine laboratory studies, including two-hour postprandial blood glucose and serum potassium, and a chest X-ray should be obtained at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with known or suspected peptic ulcer disease.

    The initial dosage of Prednisolone Syrup (Prednisolone Oral Solution, USP) may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Prednisolone Syrup (Prednisolone Oral Solution, USP) should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.

    After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of Prednisolone Syrup (Prednisolone Oral Solution, USP) for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.


    Prednisolone Syrup (Prednisolone Oral Solution, USP) is a cherry flavored red liquid containing 15 mg of prednisolone in each 5 mL (teaspoonful) and is supplied as follows:

    NDC 0527-5406-68                   240 mL

    NDC 0527-5406-70                   480 mL


    Dispense with a suitable calibrated measuring device to assure proper measuring of dose.

                                                                         DOSE/VOLUME CHART

                                                                 15 mg prednisolone   =   1 teaspoon

                                                                 10 mg prednisolone   =   2/3 teaspoon

                                                                7.5 mg prednisolone   =   1/2 teaspoon

                                                                   5 mg prednisolone   =   1/3 teaspoon

    Dispense in tight, light-resistant and child-resistant containers as defined in the USP/NF.

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do Not Refrigerate.


    Distributed by:
    Lannett Company, Inc.
    Philadelphia, PA 19136

    Rev. 02/24


    NDC 0527-5406-70

    Oral Solution, USP)

    15 mg per 5 mL

    Rx Only
    480 mL


    prednisolone syrup
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0527-5406
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    ALCOHOL (UNII: 3K9958V90M)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    WATER (UNII: 059QF0KO0R)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color    Score    
    FlavorCHERRYImprint Code
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0527-5406-68240 mL in 1 BOTTLE; Type 0: Not a Combination Product09/21/2007
    2NDC:0527-5406-70480 mL in 1 BOTTLE; Type 0: Not a Combination Product09/21/2007
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Lannett Company, Inc. (002277481)